W"H-Y" antigen/HLA complexes in chronic GVHD
In this issue of Blood, Umino and colleagues1 reveal the intricate immune interactions that contribute to chronic graft-versus-host disease (cGVHD) after alloge
Conclusions/Relevance: This elegant work expands the mechanistic understanding of alloimmunity and the enigma of cGVHD pathogenesis, while introducing an opportunity for both alloantibody-based risk stratification and therapeutic targeting for a patient-tailored approach.
Transfusion-associated Graft versus Host Disease: A Certain but Avoidable Cause of Death
Department of Hematology, Armed Forces Institute of Transfusion, Rawalpindi, Pakistan Department of Microbiology, Armed Forces Institute of Transfusion, Rawalpindi, Pakistan ABSTRACT Transfusion-associated graft versus host disease (TA-GvHD) is a rare...
Relevance: Here, we present one such case in which the maternal blood transfused to an infant cost him his life within 12 days of transfusion.
Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37713530/
Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
Relevance: Zhou et al. recently published a prognostic model for patients with chronic myelomonocytic leukemia (CMML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in this journal. This score consisted of five items: Age, Blasts, Leukocytes, Anemia, and chronic Graft vs Host Disease (ABLAG). The strongest predictor in...
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36800551/
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management...
Conclusions/Relevance: Currently, ibrutinib, ruxolitinib, and belumosudil are the only drugs that are approved by the Food and Drug Administration for steroid-refractory cGVHD. In light of the current standard management of cGVHD, the trial results indicate that ibrutinib will remain reserved for second-line therapy, which may be due to its...
Comparative transcriptome profile of mouse macrophages treated with the RhoA/Rock pathway inhibitors Y27632, Fingolimod (Gilenya), and Rezurock (Belumosudil, SLx-2119)
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923003387?via=ihub
Macrophages play a crucial role in, the currently uncurable, chronic rejection of transplants. In rodent transplantation models, inhibition of the Rho...
Conclusions/Relevance: The result of this study not only uncovers which pathways are shared or specific for these drugs but will help in the development of macrophage pathway-targeted therapies in human transplantation, MS, and GVHD. Because macrophages are the major players in immune response, tissue regeneration, renewal, and homeostasis,...